A targeted and localizing anticoagulation therapy

NU 2016-126

INVENTORS

SHORT DESCRIPTION

This technology employs a novel conjugation method that attaches a fibrin binding peptide (CREKA) to

heparin, ensuring targeted localization and maintained anticoagulant activity for medical devices.

BACKGROUND

Current anticoagulation strategies typically rely on the systemic use of heparin or its direct

functionalization on medical devices, which can be costly and expose patients to higher levels of the drug

than necessary. Existing solutions do not adequately target the anticoagulant to the precise site of clot

formation, limiting the efficacy and increasing potential side effects.

ABSTRACT

The invention introduces a composite material that covalently binds a short fibrin binding peptide

(CREKA) to heparin using a bifunctional linker, ensuring specific orientation and preserving the active

sites of both the peptide and the anticoagulant. By facilitating localized delivery of the anticoagulant to

fibrin-rich areas, such as the surfaces of vascular grafts and other medical devices, the method promises

improved clot prevention while potentially reducing overall drug dosage and associated bleeding risks.

APPLICATIONS

Prevention of clot formation on vascular grafts and prosthetic devices
Improvement of anticoagulation in catheters, hemodialyzers, and related medical devices

ADVANTAGES

Introduced in the same manner as traditional heparin delivery
Applicable to all vascular grafts and medical devices, eliminating premium costs
Reduces the required dosage of anticoagulant, minimizing patient exposure
Enhances biocompatibility through improved endothelial cell adhesion

PUBLICATIONS

None provided

IP STATUS

US Patent Pending – US-2025-0129184-A1

Direct Link:

Keywords:

Bookmark this page

Download as PDF

For Information, Contact:

Sarah Kamper

Senior Invention Manager

Northwestern University

847/491-5095

sarah.kamper@northwestern.edu